Impact of switching to single dosing regimen of antipsychotics on medication adherence in schizophrenia: A randomized controlled trial

Impact of switching to single dosing regimen of antipsychotics on medication adherence in schizophrenia: A randomized controlled trial - Impact of switching to single dosing regimen of antipsychotics on medication adherence in schizophrenia: A randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037946

Enrollment

100

Registered

2019-09-06

Start date

2019-09-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Switching multiple daily dosing regimen of antipsychotics to single dosing regimen Continuing multiple daily dosing regimen of antipsychotics

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Japanese outpatient without admission for recent at least 3 months (2) Being diagnosed with schizophrenia according to ICD-10 (3) Receiving oral antipsychotics twice or more a day without any change in type, dose, or dosing regimen of antipsychotics for at least 3 months, and not receiving long-acting injectable antipsychotics (4) Not lower than 20 years old (5) Being capable to provide informed consent

Exclusion criteria

Exclusion criteria: (1) Having serious medical conditions (2) Having a history of mental and behavioral disorders due to psychoactive substance use (3) Being pregnant or lactating (4) Being incapable to understand Japanese language (5) Having a history of blood sampling-induced vasovagal reaction (6) Being judged as inappropriate by investigators

Design outcomes

Primary

Measure	Time frame
Medication adherence at 12 weeks after intervention	—

Secondary

Measure	Time frame
Positive and Negative Syndrome Scale (PANSS); Brief Evaluation of Psychosis Symptom Domains (BE-PSD); Clinical Global Impression - Global Severity (CGI-S); Brief Assessment of Cognition in Schizophrenia (BACS); Personal and Social Performance Scale (PSP); Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS); UKU Side Effect Rating Scale (UKU-SERS); Subjective well-being under neuroleptic drug treatment short form (SWNS); Perceived Deficits Questionnaire (PDQ); Visual Analogue Scale for Distress Associated with Symptoms (VAS-DAS); blood sampling for general test, plasma assay at start and 12 weeks after intervention	—

Measure

Time frame

Positive and Negative Syndrome Scale (PANSS); Brief Evaluation of Psychosis Symptom Domains (BE-PSD); Clinical Global Impression - Global Severity (CGI-S); Brief Assessment of Cognition in Schizophrenia (BACS); Personal and Social Performance Scale (PSP); Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS); UKU Side Effect Rating Scale (UKU-SERS); Subjective well-being under neuroleptic drug treatment short form (SWNS); Perceived Deficits Questionnaire (PDQ); Visual Analogue Scale for Distress Associated with Symptoms (VAS-DAS); blood sampling for general test, plasma assay at start and 12 weeks after intervention

—

Countries

Japan

Contacts

Public ContactHodaka Yaegashi

Yamanashi Prefectural Kita Hospital Department of psychiatry

h.yaemon@hotmail.co.jp0551-22-1621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026